Otsuka Holdings (TSE: 4578) faces UK code findings over symposium webpage
The marketing watchdog found multiple breaches while distinguishing them from its most serious industry-discredit provision.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
The UK's pharmaceutical marketing watchdog found that Otsuka Europe's involvement with a sponsored symposium webpage breached 11 clauses of the industry code, according to reporting published on 22 October.
The findings concerned public-facing content promoting voclosporin outside its authorised terms and omitting required information, among other shortcomings. Otsuka accepted several breaches, including failure to maintain high standards.
The PMCPA did not find a breach of Clause 2, which concerns bringing discredit upon, or reducing confidence in, the industry. It considered that event organisers had let the company down, including by publishing contentious material absent from drafts Otsuka had reviewed. Responsibility nevertheless remained with the company.
The practical lesson is about control of sponsored content after approval. Reviewing a draft does not ensure that the published version remains compliant. For pharmaceutical businesses, external organisers and digital publishing workflows create oversight obligations that extend beyond supplying accurate slides or approving an initial page. These are code findings, not a criminal conviction.